Posted on January 08, 2018

Aamal Company Q.P.S.C., one of the region’s fastest growing diversified companies –and its fully owned subsidiary, Ebn Sina Medical – announced a distribution agreement with Turkish Company CinnaGen Ilaç, an established firm which started operating in Turkey in 2016. The deal involves importing several biotech drugs to Qatar used for medical treatment of multiple sclerosis, rheumatoid arthritis, cancer, and blood diseases.

The signing ceremony took place in Doha, with the attendance of Turkey’s ambassador to Qatar H.E. Mr. Fikret Özer, and CEO of CinnaGen Ilaç’ Dr. Ferhat Farsi and General Manager of Ebn Sina Medical, Mr. Sherif Shehata.

Sheikh Mohamed Bin Faisal Al Thani – Vice Chairman and Managing Director of Aamal Company Q.P.S.C. – commented: “We are very pleased to announce this agreement with CinnaGen Ilaç, which reflects Aamal’s persistence on exploring new international markets and creating cooperative relationships with companies that go in line with the quality standards of Aamal has set for its products. We are positive that this deal will support Ebn Sina organic growth, which include being alert to the market demands and adopt a proactive approach partnering with leading institutions to provide the local market with the best and latest pharmaceutical products to meet the increasing market needs”.

Mr. Sherif Shehata, General Manager of Ebn Sina Medical added: “I’m pleased to announce this partnership with a leading pharmaceutical firm such as CinnaGen Ilaç. As we reveal this agreement, we express our determination and commitment to secure medicine availability in Qatar – based on the recommendations of the Ministry of Health – from different resources, including Turkey, which has shown strong support to the Qatari market in the status quo. Our deal with CinnaGen Ilaç came after careful search for a well-establish partner in Turkey to provide us with such an excellent opportunity to expand our product offering”.